Drugs are widely used to sedate dementia patients. Her sons wanted to keep her off them

Billy Odell Tucker-Robinson Founder & Host — Banking With Billy Network • Financial Intelligence • Markets • World News • Independent Analysis
Published: 2026-09-30 • Permanent link

Fears lingered among investors as the news of widespread sedation of dementia patients in long-term care facilities spread. Potent medications, often prescribed to calm agitated individuals, have been used on nearly 40% of dementia patients in Michigan, according to a recent report. The medication of choice, benzodiazepines, have been linked to increased risk of falls, cognitive decline, and even death. The pharmaceutical giant, Pfizer, has been at the center of the controversy, with its medication, Xanax, being one of the most commonly prescribed sedatives.

As the nation grapples with the consequences of widespread sedation, many are left wondering about the long-term effects on dementia patients. The use of sedatives in long-term care facilities has sparked concerns about patient autonomy and the quality of care provided. The decision to prescribe sedatives to dementia patients has been met with resistance from some families, who claim that their loved ones were being medicated without their consent. The use of sedatives in long-term care facilities has raised questions about the role of pharmaceutical companies in shaping medical decisions.

Industry experts point to a broader trend of over-medicalization in the healthcare sector, where patients are increasingly being prescribed medications to manage symptoms rather than addressing the underlying causes of their conditions. Since the 1980s, the use of benzodiazepines has skyrocketed, with the number of prescriptions increasing by 70% over the past decade. The widespread use of sedatives has been linked to a rise in opioid addiction and other negative health outcomes.

Regulatory bodies are expected to take action in response to the growing concerns surrounding sedation of dementia patients. The FDA has announced plans to review its guidelines for the use of benzodiazepines in long-term care facilities, and some lawmakers have called for legislation to restrict the use of sedatives in these settings. As the debate continues, patients and families will be watching closely for any changes in the regulatory landscape, and for a shift towards more patient-centered care approaches.